Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Should You Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped down before the market opened on Tuesday . The stock had previously closed at $48.30, but opened at $43.5275. Zealand Pharma A/S shares last traded at $43.5275, with a volume of 181 shares.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ZLDPF shares. BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Zealand Pharma A/S presently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Trading Down 9.9%

The firm has a market capitalization of $3.09 billion, a PE ratio of 3.18 and a beta of 0.88. The company has a quick ratio of 23.57, a current ratio of 23.57 and a debt-to-equity ratio of 0.02. The business’s fifty day moving average price is $53.56 and its 200 day moving average price is $66.92.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.34) by $0.53. The business had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. As a group, analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.